A phase 3 study of durvalumab with or without bevacizumab as adjuvant therapy in patients with hepatocellular carcinoma (HCC) who are at high risk of recurrence after curative hepatic resection.

Journal Article (Journal Article)

Full Text

Duke Authors

Cited Authors

  • Knox, J; Cheng, A; Cleary, S; Galle, P; Kokudo, N; Lencioni, R; Park, J; Zhou, J; Mann, H; Morgan, S; Liu, X; Chin, S; Vlahovic, G; Fan, J

Published Date

  • July 2019

Published In

Volume / Issue

  • 30 Suppl 4 /

Start / End Page

  • iv51 -

PubMed ID

  • 32085192

Electronic International Standard Serial Number (EISSN)

  • 1569-8041

Digital Object Identifier (DOI)

  • 10.1093/annonc/mdz155.186


  • eng

Conference Location

  • England